Our findings that Hpo pathway inhibition or YAP activation not only inhibits HIF-2α but also NF-κB signaling in ccRCC open a possibility for developing novel therapeutics to treat ccRCC. The gene discussed is EPAS1; the disease is nonpapillary renal cell carcinoma.